List of adverse effects of nilotinib
This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.[1][2][3][4][5][6]
Very common
Very common (>10% incidence) adverse effects include:
- Headache
- Nausea
- Hypophosphataemia
- Hyperbilirubinaemia
- Alanine aminotransferase (ALT) increased
- Aspartate aminotransferase increased
- Lipase increased
- Rash
- Itchiness
- Hair loss
- Dry skin
- Muscle aches
- Fatigue
Common
Common (1–10% incidence) adverse effects include:
- Constipation
- Diarrhoea
- Vomiting
- Upper abdominal pain
- Indigestion
- Joint pain
- Muscle spasms
- Pain in extremities
- Asthenia
- Peripheral oedema
- Folliculitis
- Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
- Skin papilloma
- Eosinophilia
- Lymphopenia
- Insomnia
- Anxiety
- Depression
- Diabetes mellitus
- Hypercholesterolaemia
- Hyperlipidaemia
- Hypertriglyceridaemia
- Hyperglycaemia
- Loss of appetite
- Dizziness
- Hypoaesthesia
- Peripheral neuropathy
- Eye pruritus
- Conjunctivitis
- Dry eye (including xerophthalmia)
- Vertigo
- Flushing
- Hypertension
- Angina pectoris
- Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
- QT interval prolonged
- Palpitations
- Cough
- Dyspnoea
- Abdominal distension
- Abdominal discomfort
- Taste changes
- Flatulence
- Abnormal liver function
- Bone pain
- Back pain
- Erythema
- Hyperhidrosis
- Contusion
- Acne
- Dermatitis (including allergic, exfoliative and acneiform)
- Night sweats
- Fever without an infectious cause
- Chest pain (including non-cardiac chest pain)
- Chest discomfort
- Decreased haemoglobin
- Increased blood amylase
- Increased blood alkaline phosphatase
- Gamma-glutamyltransferase increased
- Weight increased
- Increased blood insulin
- Increased lipoprotein (including very low density and high density)
Uncommon
Uncommon (0.1–1% incidence) adverse effects include:
- Diffuse alveolar hemorrhage[7]
- Pancytopenia
- Hyperkalaemia
- Hypocalcaemia
- Hypokalaemia
- Dyslipidaemia
- Gout
- Migraine
- Paraesthesia
- Cyanosis
- Eyelid oedema
- Photopsia
- Conjunctival haemorrhage
- Hyperaemia (scleral, conjunctival, ocular)
- Peripheral arterial occlusive disease
- Arteriosclerosis
- Pleural effusion
- Jaundice
- Pancreatitis
- Gastritis
- Sensitivity of teeth
- Flank pain
- Musculoskeletal pain
- Drug eruption
- Skin pain
- Muscle weakness
- Decreased g;obulins
- Erectile dysfunction
- Pain
- Chills
- Feeling body temperature change (including feeling hot, feeling cold)
- Malaise
References
- "Complete Nilotinib information from Drugs.com". Drugs.com. Retrieved 25 January 2014.
- "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Retrieved 25 January 2014.
- "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Retrieved 25 January 2014.
- "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Retrieved 25 January 2014.
- "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220.CS1 maint: multiple names: authors list (link)
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.